Plasma 25-hydroxyvitamin D and prostate cancer risk: The Multiethnic Cohort

Park, Song-Yi; Cooney, Robert V.; Wilkens, Lynne R.; Murphy, Suzanne P.; Henderson, Brian E.; Kolonel, Laurence N.

doi:10.1016/j.ejca.2009.12.030

« Previous Next »European Journal of Cancer
Volume 46, Issue 5 , Pages 932-936, March 2010

Plasma 25-hydroxyvitamin D and prostate cancer risk: The Multiethnic Cohort

Song-Yi Park
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, 1236 Lauhala Street, Honolulu, HI 96813, USA
- Corresponding author: Tel.: +1 808 564 5947; fax: +1 808 586 2982.
Robert V. Cooney
- Natural Products and Cancer Biology Program, Cancer Research Center of Hawaii, University of Hawaii, 1236 Lauhala Street, Honolulu, HI 96813, USA
Lynne R. Wilkens
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, 1236 Lauhala Street, Honolulu, HI 96813, USA
Suzanne P. Murphy
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, 1236 Lauhala Street, Honolulu, HI 96813, USA
Brian E. Henderson
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
Laurence N. Kolonel
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, 1236 Lauhala Street, Honolulu, HI 96813, USA

Received 22 September 2009; received in revised form 12 December 2009; accepted 18 December 2009. published online 11 January 2010.

Abstract

The purpose of this study was to examine the relationship of plasma 25-hydroxyvitamin D (25(OH)D) concentrations to prostate cancer within a large multiethnic cohort in Hawaii and California using a nested case-control design. The study included 329 incidents of prostate cancer of African American, Native Hawaiian, Japanese, Latino and White ancestry, and 656 controls matched on age, race/ethnicity, date/time of blood collection and fasting status. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CI). No association with prostate cancer risk was found in an analysis based on quartiles of 25(OH)D. When clinically defined cutpoints were used, there was no increased risk for the lowest 25(OH)D concentration (OR for <20 versus 30–<50ng/ml=1.10, 95% CI=0.68–1.78), while there was a suggestive increased risk for higher concentrations (OR for ⩾50ng/ml=1.52, 95% CI=0.92–2.51). The findings from this prospective study of men in the Multiethnic Cohort do not support the hypothesis that vitamin D lowers the risk of prostate cancer. Further follow-up is warranted to determine whether the findings are consistent across ethnic groups.